Get the Stockscreener App
1.41
2.17%
0.03
Pre-market:
1.45
0.04
+2.84%
Heron Therapeutics Inc stock is traded at $1.41, with a volume of 1.52M.
It is up +2.17% in the last 24 hours and down -26.18% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.38
Open:
$1.38
24h Volume:
1.52M
Relative Volume:
0.95
Market Cap:
$216.14M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-8.8125
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+9.30%
1M Performance:
-26.18%
6M Performance:
-17.54%
1Y Performance:
-28.79%
1-Day Range:
$1.36
$1.42
1-Week Range:
$1.25
$1.42
52-Week Range:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.41 | 199.28M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
When is the best time to exit Heron Therapeutics Inc.Weekly Trade Review & Entry Point Confirmation Signals - Newser
Is Heron Therapeutics Inc. stock ready for a breakoutWeekly Investment Report & AI Based Buy and Sell Signals - Newser
Does Heron Therapeutics Inc. qualify in momentum factor screeningEarnings Recap Summary & Daily Entry Point Alerts - Newser
What’s the recovery path for long term holders of Heron Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - Newser
Heron Therapeutics Inc. stock outlook for YEARWeekly Investment Report & Entry Point Confirmation Signals - Newser
Using portfolio simulators with Heron Therapeutics Inc. includedEntry Point & Real-Time Market Trend Scan - Newser
Can machine learning forecast Heron Therapeutics Inc. recoveryFed Meeting & Risk Managed Investment Strategies - Newser
Heron Therapeutics: The View From 30,000 Feet Amid The Zynrelef Launch (NASDAQ:HRTX) - Seeking Alpha
How to use a screener to detect Heron Therapeutics Inc. breakouts2025 Top Gainers & Smart Allocation Stock Tips - Newser
Real time pattern detection on Heron Therapeutics Inc. stockIndex Update & Reliable Intraday Trade Plans - Newser
Key metrics from Heron Therapeutics Inc.’s quarterly data2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - Newser
What momentum shifts mean for Heron Therapeutics Inc.July 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
Custom strategy builders for tracking Heron Therapeutics Inc.2025 Top Decliners & Daily Profit Focused Screening - Newser
Can Heron Therapeutics Inc. expand its profit marginsWeekly Trend Report & Free Weekly Chart Analysis and Trade Guides - theviewers.co.kr
Will Heron Therapeutics Inc. face regulatory challengesCEO Change & Weekly Top Gainers Alerts - theviewers.co.kr
Tick level data insight on Heron Therapeutics Inc. volatilityWeekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser
Will Heron Therapeutics Inc. outperform the marketJuly 2025 Review & Consistent Income Trade Ideas - Newser
Heron Therapeutics Adopts Tax Benefit Preservation Plan - MSN
Is Heron Therapeutics Inc. subject to activist investor interestMarket Trend Report & Scalable Portfolio Growth Ideas - theviewers.co.kr
Is a relief rally coming for Heron Therapeutics Inc. holdersEarnings Beat & High Conviction Buy Zone Picks - Newser
Sector Rotation Brings Heron Therapeutics Inc. Into Focus2025 Winners & Losers & Accurate Entry/Exit Alerts - newsyoung.net
Technical Models Detect Momentum Build in Heron Therapeutics Inc.Weekly Trade Review & Fast Gain Swing Trade Alerts - classian.co.kr
Heron Therapeutics Inc. Stages Intraday Comeback — Trend Change2025 AllTime Highs & Trade Opportunity Analysis Reports - newsyoung.net
Signal strength of Heron Therapeutics Inc. stock in tech scannersJuly 2025 Technicals & AI Driven Price Forecasts - Newser
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Strong Sell at Zacks Research - MarketBeat
Heron Therapeutics Inc. Facing Inflection Point in Trend AnalysisJuly 2025 Patterns & Smart Investment Allocation Tips - newsyoung.net
Can Traders Expect Breakout From Heron Therapeutics Inc. This WeekJuly 2025 Chart Watch & Expert Approved Momentum Ideas - 선데이타임즈
XTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. $HRTX - MarketBeat
Adam Morgan Acquires 1,766,546 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock - MarketBeat
Informed Momentum Co LLC Takes $768,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Major Shareholder Rubric Capital Management Lp Buys 2,387,225 Shares - MarketBeat
Heron Therapeutics Inc. stock trendline breakdownJuly 2025 Fed Impact & Consistent Profit Focused Trading Strategies - Newser
How to build a dashboard for Heron Therapeutics Inc. stockTrade Analysis Summary & Community Verified Swing Trade Signals - Newser
Is Heron Therapeutics Inc. undervalued by DCF analysisRecession Risk & Entry Point Confirmation Signals - newsyoung.net
Heron Therapeutics Inc. stock volume spike explainedJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Technical analysis overview for Heron Therapeutics Inc. stockPortfolio Value Report & Verified Chart Pattern Signals - Newser
Strategic Tax Preservation as a Catalyst for Long-Term Value Creation: Heron Therapeutics' Section 382 Rights Plan and Its Implications for Biotech Investors - AInvest
How Efficient Is Heron Therapeutics Inc. at Controlling Operating CostsBull Run & AI Based Buy and Sell Signals - Newser
Heron Therapeutics Adopts Rights Plan to Protect Tax Benefits - MarketScreener
Heron Therapeutics adopts tax benefits preservation plan - TipRanks
Strategic Tax Planning as a Catalyst for Shareholder Value: Heron Therapeutics' Section 382 Rights Plan - AInvest
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.95%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):